Debate. Cerebral embolic protection systems in TAVI: there is some supportive evidence
QUESTION: Do you think that there is, currently, any evidence behind the use of cerebral protection devices in transcatheter aortic valve implantation (TAVI)? ANSWER: Former studies described that, during TAVI, loose debris like arterial wall fragments, thrombi, valve tissue, and foreign bodies ofte...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Permanyer
2023-08-01
|
| Series: | REC: Interventional Cardiology (English Ed.) |
| Online Access: | https://recintervcardiol.org/en/index.php?option=com_content&view=article&id=1125 |
| _version_ | 1797772936024686592 |
|---|---|
| author | Pilar Jiménez Quevedo |
| author_facet | Pilar Jiménez Quevedo |
| author_sort | Pilar Jiménez Quevedo |
| collection | DOAJ |
| description | QUESTION: Do you think that there is, currently, any evidence behind the use of cerebral protection devices in transcatheter aortic valve implantation (TAVI)? ANSWER: Former studies described that, during TAVI, loose debris like arterial wall fragments, thrombi, valve tissue, and foreign bodies often enters the circulation.1 These particles are the aftermath of the device making its way through the aorta towards the aortic annulus, the positioning and displacement of a calcified stenotic valve between the new valve stent and the aortic wall, and further manipulations to optimize results (postdilatation). To this date, numerous studies have been published on the safety and efficacy profile of these cerebral protection devices (CPD). Specifically, 4 randomized clinical trials have been published associated with the SENTINEL (Boston Scientific Corp., United States): MISTRAL-C,2 CLEAN TAVI,3 SENTINEL,4 and PROTECTED TAVR5 we can talk about later on. The MISTRAL-C trial used cerebral magnetic resonance imaging to demonstrate a significant reduction in the number of patients with multiple cerebral lesions (20% vs 0%; P = .03) and less cognitive impairment (4% vs 27%; P = .017). Similarly, the CLEAN TAVI trial also reported fewer novel lesions and of a smaller volume without any differences being reported in the number of clinical events in the... |
| first_indexed | 2024-03-12T21:59:02Z |
| format | Article |
| id | doaj.art-6db11ee4733f47f99e119a04d8652a2d |
| institution | Directory Open Access Journal |
| issn | 2604-7322 |
| language | English |
| last_indexed | 2024-03-12T21:59:02Z |
| publishDate | 2023-08-01 |
| publisher | Permanyer |
| record_format | Article |
| series | REC: Interventional Cardiology (English Ed.) |
| spelling | doaj.art-6db11ee4733f47f99e119a04d8652a2d2023-07-25T10:52:58ZengPermanyerREC: Interventional Cardiology (English Ed.)2604-73222023-08-015310.24875/RECICE.M23000374Debate. Cerebral embolic protection systems in TAVI: there is some supportive evidencePilar Jiménez Quevedo0Servicio de Cardiología, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria San Carlos (IdISSC), Madrid, SpainQUESTION: Do you think that there is, currently, any evidence behind the use of cerebral protection devices in transcatheter aortic valve implantation (TAVI)? ANSWER: Former studies described that, during TAVI, loose debris like arterial wall fragments, thrombi, valve tissue, and foreign bodies often enters the circulation.1 These particles are the aftermath of the device making its way through the aorta towards the aortic annulus, the positioning and displacement of a calcified stenotic valve between the new valve stent and the aortic wall, and further manipulations to optimize results (postdilatation). To this date, numerous studies have been published on the safety and efficacy profile of these cerebral protection devices (CPD). Specifically, 4 randomized clinical trials have been published associated with the SENTINEL (Boston Scientific Corp., United States): MISTRAL-C,2 CLEAN TAVI,3 SENTINEL,4 and PROTECTED TAVR5 we can talk about later on. The MISTRAL-C trial used cerebral magnetic resonance imaging to demonstrate a significant reduction in the number of patients with multiple cerebral lesions (20% vs 0%; P = .03) and less cognitive impairment (4% vs 27%; P = .017). Similarly, the CLEAN TAVI trial also reported fewer novel lesions and of a smaller volume without any differences being reported in the number of clinical events in the...https://recintervcardiol.org/en/index.php?option=com_content&view=article&id=1125 |
| spellingShingle | Pilar Jiménez Quevedo Debate. Cerebral embolic protection systems in TAVI: there is some supportive evidence REC: Interventional Cardiology (English Ed.) |
| title | Debate. Cerebral embolic protection systems in TAVI: there is some supportive evidence |
| title_full | Debate. Cerebral embolic protection systems in TAVI: there is some supportive evidence |
| title_fullStr | Debate. Cerebral embolic protection systems in TAVI: there is some supportive evidence |
| title_full_unstemmed | Debate. Cerebral embolic protection systems in TAVI: there is some supportive evidence |
| title_short | Debate. Cerebral embolic protection systems in TAVI: there is some supportive evidence |
| title_sort | debate cerebral embolic protection systems in tavi there is some supportive evidence |
| url | https://recintervcardiol.org/en/index.php?option=com_content&view=article&id=1125 |
| work_keys_str_mv | AT pilarjimenezquevedo debatecerebralembolicprotectionsystemsintavithereissomesupportiveevidence |